Quest Diagnostics director Dr. Helen I. Torley will not seek re-election; board size reduced to 9

QUEST DIAGNOSTICS INC

Dr. Torley, President & CEO of Halozyme, chose not to stand for re-election at the May 18, 2022 annual meeting.
Board reduced its size from 10 to 9 directors, effective at the annual meeting.
Dr. Torley cited a desire to focus on board service for companies developing innovative medicines.
No disagreement with the company was disclosed regarding her departure.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Helen I. Torley

Director

DGX · QUEST DIAGNOSTICS INC

Effective: 2022-05-18
Filed: March 2, 2022, 6:59 PM ET

On February 24, 2022, Dr. Helen I. Torley informed the Company of her decision to not seek re-election to the Company’s Board of Directors (the “Board”) at the Company’s Annual Meeting of Stockholders to be held May 18, 2022 (the “Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Helen I. Torley departed as Director at QUEST DIAGNOSTICS INC.

Action: not seek re-election
Role: Director

Exact text from the filing

On February 24, 2022, Dr. Helen I. Torley informed the Company of her decision to not seek re-election to the Company’s Board of Directors (the “Board”) at the Company’s Annual Meeting of Stockholders to be held May 18, 2022 (the “Annual Meeting”).

View on SEC.gov

QUEST DIAGNOSTICS INC filing history →

Source: SEC EDGAR

accession 0001022079-22-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.